LifeMD (LFMDP) Common Equity (2012 - 2025)

LifeMD has reported Common Equity for 14 years, with the latest figure at $23.2 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 406.54% year-over-year to $23.2 million; the trailing twelve-month figure through Dec 2025 stood at $23.2 million (up 406.54% YoY), and the FY2025 full-year result was $23.2 million, up 406.54% from the prior year.
• Common Equity for Q4 2025 stood at $23.2 million, up from $3.4 million in the prior quarter.
• The five-year high for Common Equity was $23.2 million in Q4 2025, with the low at -$243.2 million in Q2 2025.
• Historically, Common Equity has averaged -$25.2 million across 5 years, with a median of -$3.5 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity jumped 1541.84% — and 2025, when it plunged 12757.07%.
• LifeMD's Common Equity stood at $21.7 million in 2021, then tumbled by 154.69% to -$11.9 million in 2022, then soared by 135.29% to $4.2 million in 2023, then sank by 280.33% to -$7.6 million in 2024, then surged by 406.54% to $23.2 million in 2025.
• The last three Common Equity figures came in at $23.2 million (Q4 2025), $3.4 million (Q3 2025), and -$243.2 million (Q2 2025), per Business Quant data.